Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Amgen's Capital Expenditure for the
three
months ended in Mar. 2026 was €-615.88 Mil. Its Revenue for the
three
months ended in Mar. 2026 was €7,454.57 Mil.
Hence, Amgen's Capex-to-Revenue for the
three
months ended in Mar. 2026 was 0.08.
Amgen (XTER:AMG) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Amgen Capex-to-Revenue Related Terms
Amgen Capex-to-Revenue Historical Data
* Premium members only.
The historical data trend for Amgen's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:AMG vs GILD, PFE, BMY: Capex-to-Revenue Comparison
For the Drug Manufacturers - General subindustry, Amgen's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Capex-to-Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Amgen's Capex-to-Revenue falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (XTER:AMG) has a Capex-to-Revenue of 0.08 as of Mar. 2026. Capex to Revenue ratio measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. View historical data on Amgen and its competitors.
Is Amgen's Capex-to-Revenue too high?
Amgen's current Capex-to-Revenue is 0.08. Overall, Amgen has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Capex-to-Revenue compare to GILD and PFE?
Amgen's Capex-to-Revenue of 0.08 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Revenue for a Drug Manufacturers company?
A good Capex-to-Revenue depends on the Drug Manufacturers industry context. However, Capex-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Revenue mean?
A high Capex-to-Revenue can signal that a stock is expensive relative to its fundamentals. Capex to Revenue ratio measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. View historical data on Amgen and its competitors. Amgen's current Capex-to-Revenue is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (XTER:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €310.77, compared to a current price of €305.05 — trading 1.8% below its estimated fair value. The current Capex-to-Revenue is 0.08. Amgen's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Revenue calculated?
Capex-to-Revenue is calculated from a company's financial statements. For Amgen (XTER:AMG), the current Capex-to-Revenue is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (XTER:AMG) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be undervalued.
The current stock price of €305.05 is trading 1.8% below its estimated GF Value™ of €310.77.
GuruFocus considers Amgen to be Fairly Valued.
Key valuation signals for XTER:AMG:
Capex-to-Revenue: 0.08
GF Value™: €310.77 vs. price of €305.05 (1.8% below fair value)
No single metric tells the full story. See the XTER:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
91GF Score
Get the complete analysis for XTER:AMG
Capex-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:AMG has been successfully added to your 
